FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 320:817-821 March 30, 1989 Number 13 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

In a double-blind trial comparing two thrombolytic agents as treatment for acute myocardial infarction, we randomized 270 consecutive patients an average (+/- SD) of 2.5 +/- 0.6 hours after the onset of chest pain from a first myocardial infarction--135 to receive intravenous streptokinase (1.5 million units over 30 minutes) and 135 to receive intravenous recombinant tissue plasminogen activator (rt-PA) (100 mg over three hours). The primary end point was left ventricular function as assessed by cineangiography performed three weeks after infarction. The effects of the two agents on left ventricular function were similar. The ejection fraction was identical (58 +/- 12 percent) in both groups. The end-systolic volume was 61 +/- 29 ml in the streptokinase group and 66 +/- 31 ml in the rt-PA group (P not significant). Patency rates at three weeks for the infarct-related artery were also similar (75 percent in the streptokinase group and 76 percent in the rt-PA group). Reinfarction rates at 30 days were the same (5 percent) in both groups. One patient had a fatal intracerebral hemorrhage 13 hours after receiving rt-PA, and another had a fatal cerebellar hemorrhage 21 hours after receiving rt-PA for reinfarction nine days after treatment with streptokinase. An intention-to-treat analysis revealed that mortality at 30 days was 3.7 percent in the rt-PA group as compared with 7.4 percent in the streptokinase group (P greater than 0.2). Follow-up for a mean of 9.0 months revealed no significant difference in survival; we observed 12 deaths (8.9 percent) in the streptokinase group and 8 deaths (5.9 percent) in the rt-PA group (P = 0.34). We conclude that rt-PA and streptokinase, in the doses given, have similar effects on left ventricular function after a first myocardial infarction. Because of the small number of deaths, it is not possible to determine whether their effects on mortality are similar.

Source Information

Green Lane Hospital, Auckland, New Zealand.

This article has been cited by other articles:

• Dundar, Y., Hill, R., Dickson, R., Walley, T. (2003). Comparative efficacy of thrombolytics in acute myocardial infarction: a systematic review. QJM 96: 103-113 [Abstract] [Full Text]  
• Ohman, E. M., Harrington, R. A., Cannon, C. P., Agnelli, G., Cairns, J. A., Kennedy, J.W. (2001). Intravenous Thrombolysis in Acute Myocardial Infarction. Chest 119 : 253S-277S [Full Text]  
• Van de Water, N. S., French, J. K., Lund, M., Hyde, T. A., White, H. D., Browett, P. J. (2000). Prevalence of factor v leiden and prothrombin variant g20210a in patients age <50 years with no significant stenoses at angiography three to four weeks after myocardial infarction. J Am Coll Cardiol 36: 717-722 [Abstract] [Full Text]  
• French, J. K., Hyde, T. A., Straznicky, I. T., Andrews, J., Lund, M., Amos, D. J., Zambanini, A., Ellis, C. J., Webber, B. J., McLaughlin, S. C., Whitlock, R. M. L., Manda, S. O. M., Patel, H., White, H. D. (2000). Relationship between corrected TIMI frame counts at three weeks and late survival after myocardial infarction. J Am Coll Cardiol 35: 1516-1524 [Abstract] [Full Text]  
• French, J. K., Hyde, T. A., Patel, H., Amos, D. J., McLaughlin, S. C., Webber, B. J., White, H. D. (1999). Survival 12 years after randomization to streptokinase: the influence of thrombolysis in myocardial infarction flow at three to four weeks. J Am Coll Cardiol 34: 62-69 [Abstract] [Full Text]  
• White, H. D., Van de Werf, F. J. J. (1998). Thrombolysis for Acute Myocardial Infarction. Circulation 97: 1632-1646 [Abstract] [Full Text]  
• French, J. K, Williams, B. F, Hart, H. H, Wyatt, S., Poole, J. E, Ingram, C., Ellis, C. J, Williams, M. G, White, H. D (1996). Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction. BMJ 312: 1637-1641 [Abstract] [Full Text]  
• Benedict, C. R., Refino, C. J., Keyt, B. A., Pakala, R., Paoni, N. F., Thomas, G. R., Bennett, W. F. (1995). New Variant of Human Tissue Plasminogen Activator (TPA) With Enhanced Efficacy and Lower Incidence of Bleeding Compared With Recombinant Human TPA. Circulation 92: 3032-3040 [Abstract] [Full Text]  
• Gardell, S. J. (1993). The Search for the Ideal Thrombolytic Agent: Maximize the Benefit and Minimize the Risk. Toxicol Pathol 21: 190-198 [Abstract]  
• Sherry, S., Marder, V. J. (1991). Streptokinase and Recombinant Tissue Plasminogen Activator (rt-PA) Are Equally Effective in Treating Acute Myocardial Infarction. ANN INTERN MED 114: 417-423 [Abstract]  
• Collen, D. (1990). Coronary Thrombolysis: Streptokinase or Recombinant Tissue-Type Plasminogen Activator?. ANN INTERN MED 112: 529-538 [Abstract]  
• Krichbaum, D. W., Trivedi, D. A. (1990). Thrombolytic Therapy in Acute Myocardial Infarction. Journal of Pharmacy Practice 3: 332-348  
• (1989). COMPARING THROMBOLYTICS: STREPTOKINASE AND TPA HAVE SIMILAR EFFECTS. JWatch General 1989: 2-2 [Full Text]